Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCryst Pharmaceuticals has reported a net loss of $9.1m for the fourth quarter ended 31 December 2010, compared to a net income of $15.2m during the same period in 2009.
Subscribe to our email newsletter
Fourth quarter 2010 R&D expenses decreased to $23.6m from $31.6m in last year, driven by lower development costs associated with the peramivir and forodesine clinical programs.
Total revenues of $17.8m consisted primarily of reimbursement of collaboration expenses, including $14.9m from the contract with the Department of Health and Human Services (HHS) for the continued development of iv peramivir and the recognition of $1.1m in grant income from the US Government’s Qualifying Therapeutic Discovery Project (QTDP) program.
For the full year ended 31 December 2010, net loss was $32.7m, compared to a net loss of $13.5m for the same period in 2009.
Full year 2010 total revenues decreased to $63.5m from $74.6m in 2009.
In addition, BioCryst recognized less revenue from its collaboration with Mundipharma during 2010 compared to 2009.